Background: An economic evaluation was undertaken alongside a randomized phase III trial comparing three regimens for metastatic breast cancer (MBC).
introduction
Despite major advances in the medical field and reductions in the prevalence of disease in recent years, breast cancer remains a commonly occurring malignancy and a leading cause of mortality in women worldwide. It is responsible for 500 000 female deaths each year and accounts for 7% of all cancer deaths [1] . Because it affects even younger women, it is responsible annually for 5.5 million lost life years and for 6.2 million disability-adjusted life years (DALYs), accounting for 8% of the total life years lost and 8% of DALYs [1] .
In this context, it should be easy to appreciate why breast cancer also imposes an enormous economic burden upon societies. In the United States, for instance, it has been estimated that the economic burden of breast cancer in 2004 was 8.1 billion US$ accounting for 11.2% of the total economic burden of cancer. The above-mentioned figure does not include direct medication payments, which in the case of breast cancer patients may account for up to 10% of total breast cancer cost. In addition, the above figure does not include the indirect cost attributed to breast cancer. The total indirect annual cost of all cancers in the United States has been estimated at 190 billion US$ in 2004 prices [2] . Breast cancer affects many economically active individuals and is characterized by high prevalence and morbidity, which justify a high portion of the above figure and imply that its indirect burden may be much higher than its direct cost upon the health services.
The survival of breast cancer patients depends strongly on the disease stage at diagnosis and the effectiveness of the implemented therapies [3] . A recent multicenter, randomized phase III clinical trial was set up to evaluate the safety, effectiveness and quality of life (QoL) associated with three different, taxane-based regimens in the treatment of metastatic breast cancer (MBC) [4] . Resources are scarce and in light of ever-increasing demand for health-care provisions, strong pressure exists to maximize the health benefit gained from the money allocated to therapies. For this reason, it is important to study the cost effectiveness of alternative therapeutic options and this is especially important in the case of expensive therapies such as the ones discussed here, which represent a large portion of the cancer-related budget. Thus, an economic evaluation was undertaken alongside the clinical trial to assess whether the regimens under investigation offer value for money in the treatment of MBC in the context of the National Health Service in Greece.
materials and methods patients and treatments
The present study represents a cost-utility analysis conducted alongside a clinical trial, which recruited 437 women (416 eligible) with histologically proven MBC, who were randomized to three groups and were followed for a median period of 34 months [4] . Patients in group A were treated with paclitaxel (Taxol, Bristol-Myers Squibb, Princeton, USA) 175 mg/m 2 over 3 h followed by carboplatin (ParaplatinÒ, BristolMyers Squibb, Princeton, USA) at an area under the curve of 6, in 500 ml normal saline given as a 30-min infusion immediately after the end of paclitaxel infusion, every 3 weeks for six cycles [(paclitaxel with carboplatin (PCb)]. Patients randomized to group B were treated with gemcitabine (GemzarÒ, Eli Lilly, Indianapolis, USA) 1000 mg/m 2 dissolved in 500 ml normal saline, administered as a 30-min infusion on days 1 and 8 followed by docetaxel (Taxotere, Aventis Pharma, Dagenham, UK) 75 mg/m 2 given as a 1-h infusion on day 8 only, every 3 weeks for six cycles [gemcitabine with docetaxel (GDoc)]. Finally, patients randomized to group C received weekly paclitaxel (Pw) 80 mg/m 2 over 1 h for 12 weeks. Patients had to go through a series of laboratory and imaging diagnostic examinations and received additional adequate medical treatment before, during and after chemotherapy administration, as deemed necessary. Such medical treatment for instance included growth factors, hormonal therapy (HT), bisphosphonates, trastuzumab, antibiotics and others. After the completion of chemotherapy, all patients were followed every 3 months unless otherwise indicated. The economic study was on the basis of resource utilization and outcome data referring to all the 416 eligible patients entered in the trial. Data collection was designed prospectively and all data were collected through the trial Case Report Forms and were entered in the main electronic trial database for analysis.
evaluation and outcome measurement
The trial collected data on patient safety, efficacy, QoL and resource utilization. Treatment effectiveness was measured in terms of mean patient survival per treatment group [5] [6] [7] . Survival was calculated as the time from randomization to death or loss to follow-up or to the end of study period. The study also collected QoL measurements by means of the EQ-5D instrument [4, [8] [9] [10] [11] . The utilities derived were used to adjust individual patient survival for QoL and thus to estimate quality-adjusted life years (QALYs) on a patient basis. The European tariffs were used for the determination of utility scores and QALYs were estimated, at patient level, as the product of patient survival by the average utility score over the period of follow-up. In this context, the evaluation reported incremental cost per life year saved and incremental cost per QALY saved. The time horizon was that of the trial and the perspective that of the Greek National Health Service. Hence, effects and outcomes at the adjuvant setting, therapies outside the trial and indirect costs were not considered. In the sensitivity analysis, both cost and effects were discounted at 3.5%. The trial design reflects, to a large extent, the management of patients in the normal setting and it does not impose additional resource utilization patterns; hence, it has high external validity.
cost measurement
In the Greek National Health Service, physicians are employed on a salary basis. Hospitals are reimbursed for their services by Insurance Sickens Funds on a fee-for-service basis. The fees are common across the entire public sector and are published of the official Government Gazette. To estimate the treatment cost for each patient, individual data on resource use were combined with unit price data, obtained from national sources and the database of the participating hospitals. More specifically, total patient treatment cost includes costs of the entire follow-up period, chemotherapy, other medications, laboratory examinations and hospitalizations for drug administration, adverse events and health deterioration. The study did not evaluate the cost of adjuvant and secondline chemotherapy because that was beyond its perspective. It also did not account for the use of radiotherapy; however, a previous study has shown that the marginal of radiotherapy in the Greek National Health Service (NHS) setting is not significant in terms of cost [12] . This is because radiotherapy involves a substantial start-up investment, but subsequently has low marginal variable cost. In more detail, the cost of chemotherapy in each cycle was calculated as the product of the exact milligrams of dose given to each patient by the drug cost per milligram. It was assumed that there is no drug waste because it is a common practice that the surplus from a vial is used for the next patient. This is a common approach to other cancer evaluations in Greece and elsewhere [12] [13] [14] [15] [16] [17] [18] . Each administration of chemotherapy involved a day case and each follow-up an outpatient visit. The cost of all other drugs was calculated in a similar manner based on the dose given. Data on the use of other medications were obtained from the trial database on a per-patient basis. The cost of hospitalizations due to adverse events was calculated as the product of the number of inpatient days by the cost per inpatient day. The cost of laboratory and imaging diagnostic examinations was estimated as the product of the number of such examinations per patient, during the period of follow-up, by the cost of each of them. This information was also available on a patient basis from the trial database. Unit prices reflect year 2007 Euro (EUR) prices; it needs to be pointed out that such prices are determined by the government and they are common across all public NHS hospitals. While drug prices are similar in the private sector, the remaining resources (hospitalization, laboratory and imaging examinations) have different prices and thus the analysis reflects only the public sector. What matters though is the incremental cost difference between alternative treatments. Even if, in absolute terms, the cost of treatment in the private sector is different, marginal cost effectiveness of therapies may be the same.
analysis
For economic evaluation purposes, mean survival corresponds to the mean time of follow-up, for each patient until death or date of last contact. Individual survival data were combined with the EQ-5D score to estimate QALYs on a per-patient basis. Individual resource utilization data were combined with price data to estimate patient treatment cost and its components. The dataset was then used to get mean estimates and subsequently incremental cost per life year saved and incremental cost per QALY saved with one treatment over another. There are not explicitly set cost-effectiveness thresholds, but in most health-care systems, an incremental cost-effectiveness ratio <40 000-50 000 EUR indicates acceptable therapies, while therapies with higher ratios are at increasing risk of being rejected [19] [20] [21] .
The distribution of treatment cost is rarely normal, as it is skewed from outliers (patients who require far more recourses than the average norm) and truncated at zero, as cost is a positive parameter. In this context, to address uncertainty, it is a standard approach nowadays to employ bootstrapping and to compute cost-effectiveness acceptability curves [5, 22] . Specifically, from the raw dataset-containing cost, survival and the quality-adjusted survival per patient-5000 new datasets were drawn using random sampling. Mean values for the parameters of interest were obtained from each dataset and were used to construct a new matrix with 5000 observations. The obtained mean values of the bootstrapped dataset represent unbiased estimations of the population parameters under investigation; their variability measures were also used to estimate uncertainty appropriate intervals using the percentile method [5] . Information presented on cost, effectiveness and cost effectiveness includes mean values, standard deviations, uncertainty intervals (UIs) and ranges. The distribution of the 5000 incremental cost-effectiveness ratios was also used to plot cost-effectiveness acceptability curves, a continuous uncertainty measure for the costeffectiveness ratio. These curves depict the likelihood for different costeffectiveness ratios to hold true given the data at hand.
There were no major issues with censored and missing data. Patients who died from the disease or from any other cause were considered as events. The study employed a dedicated data collection team and thus the dataset was quite complete. Imputation based on regression analysis was used for missing imaging data. Survival and other resource utilization were the independent variables. Sensitivity analysis was carried out to find out whether this approach had any impact on the results. Cost effectiveness and its components may vary significantly in different patient subsets. Thus, additional analyses were carried out according to patient performance status (PS), age and other characteristics. All economic evaluation analysis was performed according to the treatment actually received (PCb: 131, GDoc: 134, Pw: 133, excluding 13 patients who have never started treatment and 5 with incomplete medical records).
results

health outcomes
The trial sample included 136 patients in group A, 144 in group B and 136 in group C. Their characteristics and related information are given in detail elsewhere [4] . Nonetheless, for the purposes of the evaluation, some points are worth considering in brief. One-third of the patients had received anthracycline-containing adjuvant chemotherapy and 26% received trastuzumab. The majority of the chemotherapeutic cycles were given at the doses and time scheduled. In terms of safety, there were some differences between groups, but they were presumably reflected or captured in the hospitalization and resource utilization and QoL data. At a median follow-up of 34 months, 52% of the patients in group A, 56% in group B and 43% in group C died. Median survival times for the three groups were 29.9 months (range 0.01-54.6+), 26.9 months (range 0.01-51.4) and 41.0 months (range 0.92-56.9+), respectively (log-rank P = 0.037). The difference in survival between groups C and B was significant (log-rank P = 0.01) [4] . Parametric analysis indicated that the survival difference between groups C and B was not affected by the patient PS, while the survival difference between group C and A was statistically significant only for patients with PS one (P = 0.01, treatment by PS interaction P = 0.03). The analysis also revealed that adjuvant chemotherapy and more metastatic sites were significant adverse prognostic factors for survival, while maintenance HT and better PS significantly decreased the hazard of death [4] . Finally, while QoL was not different across treatment groups, it improved significantly during the treatment and follow-up period. The cost analysis presented here was carried out on 398 patients, excluding 13 patients who never started treatment and five with incomplete medical records. All patients were analyzed according to actual treatment given.
unit prices and resources Table 1 presents the unit cost data employed in the analysis. It is important to note that drug prices in this context refer to the hospital setting and hence by default are discounted compared with retail drug prices. Table 2 includes information on the percentage of patients who used expensive resources in each group and the average number of resources used in each group. It should be noted that, due to the differences in the method of delivery and the safety and tolerability of the alternative treatment regimens, there are in some cases statistically significant differences in the use of the resources. In particular, 30% of patients were hospitalized in group B, versus 11% in group A and 19% in group C (P < 0.001). Also, more patients in the second group (43%) received bisphosphonates compared with the first (28%) and the third group (30%) (P = 0.02). Similar is the situation in relation to the granulocyte colony-stimulating factor (G-CSF) use, 57% in the second group versus 40% and 30% in the first and third group, respectively (P < 0.001). The second group was also associated with more inpatient hospitalization days (0.53, 1.68 and 0.48, in groups A, B and C, respectively). In terms of day cases, these were on average 5.76, 10.30 and 12.59, in groups A, B and C, respectively. The second group was associated with a higher mean bisphosphonate and G-CSF dose given (760 and 890, respectively) compared with the third group (481 and 411, respectively). Finally, there were statistically significant differences between the three groups in terms of the laboratory tests carried out. Table 3 includes data on the cost of treatment and its components per treatment arm. Raw data are skewed (skewness: PCb, 1.11; GDoc, 0.26; Pw, 1.08; kyrtosis: PCb, 1.99; GDoc, 1.07; Pw, 2.29) and therefore the data presented in Table 3 are those obtained from bootstrapping. As indicated in Figure 1 for the case of total treatment cost per therapy, these data follow almost a normal distribution and hence their UIs and the inferences based on them are more robust. The total treatment cost (EUR) in group A is 20 498 (95% UI 19 044-22 020; range 17 647-23 258), in group B is 19 343 (95% UI 18 088-20 570; range 16 743-21 535) and in group C is 20 578 (95% UI 19 249-21 985; range 18 126-23 058). Hence, the second group is the one with the lower cost followed by the first and third groups, but these differences are not statistically significant. Chemotherapy accounts for 59% of the total cost of treatment, the remaining medications for 25% while the remaining 16% of the cost involves hospitalizations and examinations. Details on each of the components of the total treatment cost are depicted in Table 3 . After chemotherapy and imaging, the original article Annals of Oncology treatment with the highest cost is trastuzumab, bisphosphonates, erythropoietin, G-CSF, HT, hospitalizations and laboratory tests. There was a significant difference in the use of G-CSF between group B (876, 95% UI 701-1063) and group C (397, 95% UI 266-542), in hospitalizations in favor of group A compared with the other two groups (PCb 464, 95% UI 421-521; GDoc 880, 95% UI 809-957; Pw 947, 95% UI 892-1004), as well as with respect to laboratory examinations (PCb 203, 95% UI 185-222; GDoc 255, 95% UI 227-285; Pw 350, 95% UI 309-394).
treatment cost
cost effectiveness
The cost-effectiveness results revealed that group B (GDoc) is the least effective treatment, and group C (Pw) is the most effective of the three therapies. In particular, mean survival was In summary, GDoc is the least costly and least effective treatment, Pw is the most costly and most effective treatment and PCb is in between the other two treatments in terms of cost and effectiveness. The incremental cost-effectiveness ratios of 
Annals of Oncology original article
PCb over GDoc and Pw over PCb are presented in In this context, it should be excluded and the proper measure to study is the incremental cost per life year saved of Pw versus GDoc, which is 3660 (95% UI dominance-9261, range dominance-14 664). The UI indicates that the true ratio lies in the range between dominance of Pw over GDoc to 9261 per life year saved. It should also be noted that the maximum incremental costeffectiveness ratio between Pw and GDoc in the bootstrapped dataset is 14 664. The cost-effectiveness acceptability curve in Figure 2 indicates that there is a high likelihood that Pw may be a very cost-effective therapy option even for quite low economic thresholds. As depicted in Figure 3 and the righthand side of Table 4 , this holds true when QoL is considered. In particular, the cost (EUR) per QALY of Pw compared with GDoc is 3596 (95% UI dominance-8956, range dominance-15 154).
further analyses
As the present clinical and economic evaluation involves patients with a severe illness, the time horizon is not long enough and discounting of cost and effect is not expected to have an impact on the results. An analysis was undertaken where treatment cost, survival and quality-adjusted survival were discounted at 3.5%. Indeed, the incremental cost per life year saved with Pw compared with GDoc was 3410 (95% UI dominance-9057, range dominance-13 366), quite close to the undiscounted results. PCb was again dominated by extended dominance. Furthermore, the incremental cost per QALY saved with Pw compared with GDoc was 3361 (95% UI dominance-8965, range dominance-13 547). Thus, discounting has a minor impact upon cost effectiveness. Table 5 presents results for various patient groups. At those with PS zero, the incremental cost-effectiveness ratio of Pw over GDoc raises to 6878 (95% UI dominance-20 158), while for patients at PS one, Pw dominates (95% UI dominance-9941). The results also indicate that Pw dominates GDoc irrespective of whether the patient receives trastuzumab or not and in the case where there is no HER2 overexpression. In the case of HER2 overexpression, cost effectiveness raises to 26 162 (95% UI dominance-227 270). Finally, when patients receive HT, PCb, paclitaxel with carboplatin; GDoc, gemcitabine with docetaxel; Pw, weekly paclitaxel; USs, Ultra sounds. 
discussion
Regardless of the health-care system, the budget spent each year on drugs in general and on cancer drugs specifically is significant. New medications increase safety and efficacy over existing ones, but this usually comes at a price. The later in combination with the fact that the prevalence of cancer is high, that a number of cycles of therapy usually delivered and that other expensive drugs and resources are deployed in the management of patients, makes it easy to understand why the economics of cancer care are important. On the other hand, alternative treatments differ in terms of their safety, tolerability, efficacy and impact on QoL. Thus, it is important 
Annals of Oncology original article
to summarize somehow and know the value for money we derive from different uses and make decisions aiming to maximize the benefit for society from the limited existing resources. The life expectancy of patients with MBC depends greatly upon the efficacy of the chemotherapy administered to them. A multicenter, randomized phase III clinical trial was set to evaluate the clinical and economic efficiency of three different taxane-based regimens used in the treatment of MBC. The management of patients in the trial reflected reallife handling of patients with this disease in Greece, without extra resources being employed compared with usual care. Thus, it has high external validity and carries little design bias to the economic evaluation. The economic analysis in turn was undertaken according to established methodological standards for this type of research. It is important to note that, apart from efficacy and safety, comprehensive sets of resource utilization and unit price data were gathered from the participating centers since it was important that they were collected directly in the context of the trial. It was also important that QoL was accounted and utilities were collected directly from patients by means of the EQ-5D. Furthermore, appropriate statistical techniques were used to deal with uncertainty, which is often an issue in trials that are powered to deal with a clinical rather than an economic hypothesis.
There were three regimens under evaluation: paclitaxel coadministered with carboplatin (PCb), gemcitabine coadministered with docetaxel (GDoc) and paclitaxel given alone on a weekly basis (Pw). From the trial data, it was estimated that GDoc is the least costly (19 343, 95% UI 18 088-20 570) but also the least effective treatment (21.4 months, 95% UI 19.4-23.4; 14.5 quality-adjusted months, 95% UI 13.0-16.0). Pw on the other hand is the most costly (20 578, 95% UI 19 249-21 958) and also the most effective treatment (25.5 months, 95% UI 23.3-27.6; 18.6 quality-adjusted months, 95% UI 16.9-20.4). PCb is dominated by the other two alternatives. In this context, the incremental cost per life year saved of Pw versus GDoc is 3660 (95% UI dominance-9261) and the cost per QALY saved is 3596 (95% UI dominance-8956). Given the underlying data, these results seem quite robust. It appears that the cost-effectiveness ratio of Pw monotherapy versus GDoc combination therapy is almost certainly <15 000 which represents a value where most of the health-care systems fund new therapy options. There is also a high likelihood that the true ratio may even be much lower. Thus, given these data, the monotherapy Pw should be a preferred treatment option.
These results should be interpreted and considered from the perspective and in the context of the specific clinical and economic evaluations undertaken. It involves specific regimens, In particular, economic evaluation involves the aggregation and analysis of clinical, QoL and economic data, which are quite different and often these processes involve assumptions, special analytical techniques and analysis models. Additionally, it is not always possible to capture data on all important parameters. Thus, such evaluations are always prone to a certain degree of bias and uncertainty, which is difficult to evaluate. In this context, economic evaluation is not a panacea but only an additional tool to guide better decisions in the health-care system context and to aid decision makers to achieve better economic and clinical efficiency and excellence. In light of these shortcomings, it should be noted that this particular case seems rather robust and the conclusions rather reliable, as a therapy option which appears to have an advantage in terms of its effectiveness, also appears to be associated with quite low and attractive extra economic burden.
references
